RAndomized Clinical Trial Of NAfamostat Mesylate, A Potent Transmembrane Protease Serine 2 (TMPRSS2) Inhibitor, in Patients with COVID-19 Pneumonia

Even though SARS-CoV-2 was declared by WHO as constituting no longer a public health emergency, the development of effective treatments against SARS-CoV-2 infection remains a critical issue to prevent complications, particularly in fragile patients. The protease inhibitor nafamostat, currently used...

Descripción completa

Detalles Bibliográficos
Autores principales: Seccia, Teresa Maria, Shagjaa, Tungalagtamir, Morpurgo, Margherita, Caroccia, Brasilina, Sanga, Viola, Faoro, Sonia, Venturini, Francesca, Iadicicco, Girolama, Lococo, Sara, Mazzitelli, Maria, Farnia, Filippo, Fioretto, Paola, Kobayashi, Yusuke, Gregori, Dario, Rossi, Gian Paolo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2023
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607860/
https://www.ncbi.nlm.nih.gov/pubmed/37892756
http://dx.doi.org/10.3390/jcm12206618

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10607860/
https://www.ncbi.nlm.nih.gov/pubmed/37892756
http://dx.doi.org/10.3390/jcm12206618

Ejemplares similares